Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to -$191.7 million.

  • Coherus Oncology's Enterprise Value fell 9619.51% to -$191.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$191.7 million, marking a year-over-year decrease of 9619.51%. This contributed to the annual value of -$126.0 million for FY2024, which is 699.71% down from last year.
  • Latest data reveals that Coherus Oncology reported Enterprise Value of -$191.7 million as of Q3 2025, which was down 9619.51% from -$237.6 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Enterprise Value peaked at -$82.4 million during Q1 2025, and registered a low of -$468.7 million during Q3 2021.
  • Moreover, its 5-year median value for Enterprise Value was -$191.7 million (2022), whereas its average is -$236.6 million.
  • Per our database at Business Quant, Coherus Oncology's Enterprise Value crashed by 10672.65% in 2021 and then surged by 6827.6% in 2025.
  • Over the past 5 years, Coherus Oncology's Enterprise Value (Quarter) stood at -$417.2 million in 2021, then surged by 54.05% to -$191.7 million in 2022, then surged by 38.57% to -$117.7 million in 2023, then decreased by 7.0% to -$126.0 million in 2024, then tumbled by 52.13% to -$191.7 million in 2025.
  • Its Enterprise Value was -$191.7 million in Q3 2025, compared to -$237.6 million in Q2 2025 and -$82.4 million in Q1 2025.